Novel fluoroimmunoassay for ovarian cancer biomarker CA-125

Sok, Davin; Clarizia, Lisa-Jo A.; Farris, Leslie R.; McDonald, Malcolm

doi:10.1007/s00216-008-2569-8

Cited by 33 publications

(17 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ELISA assay was performed according to manufacturer's in- * Level of Detection (LOD) was ≤0.63 ng/mL as defined above. The %CV was also calculated; value and SD of blank were consistent with previously published reports [12,13].…”

Section: Elisa Assay Methodssupporting

confidence: 83%

“…In this study, an assay was developed for the detection of the sECD-HER-2/neu protein utilizing the ALYGNSA system consisting of a protein biolinker (Protein G') and poly (methyl methacrylate) or PMMA, a thermoplastic polymer. The unique interaction of Protein G' with PMMA has been demonstrated to improve human IgG capture antibody alignment/orientation [12] and provide greater sensitivity in detection of cancer biomarkers CA-125 [13] and PSA [14].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Enhanced immuno-detection of shed extracellular domain of HER-2/neu

Chourb¹,

Mackness²,

Farris³

et al. 2009

Health

View full text Add to dashboard Cite

HER-2/neu oncogene is over-expressed and amplified in patients associated with metastatic breast cancer. An increased level (>15 ng/mL) in the shed extracellular domain (sECD-HER 2/neu) is indicative of the potential presence and associated progression of this disease. A fluorescent ELISA incorporating the newly developed ALYGNSA antibody-orientation system revealed a 10-fold increase in sensitivity (≤0.63 ng/mL) of sECD-HER 2/neu when compared to a control standard ELISA kit (≤7.5 ng/mL). This enhanced mode of detection has the potential to not only address breast and other cancers per se but also permit an in depth evaluation of "shed extracellular domains", in general, and the role of these "proteolytic derived factors" in physiological signalling at normal levels.

show abstract

Section: Elisa Assay Methodssupporting

confidence: 83%

Section: Introductionmentioning

confidence: 99%

Enhanced immuno-detection of shed extracellular domain of HER-2/neu

Chourb¹,

Mackness²,

Farris³

et al. 2009

Health

View full text Add to dashboard Cite

show abstract

“…A fluorescent immunoassay was recently developed employing the ALYGN-SA antibody-orientation system that has been used to measure CA125 levels. This system displayed significantly increased sensitivity and should permit better identification and monitoring of ovarian cancer [3].…”

Section: What Is Known About Ca125 As a Clinical Tumor Marker?mentioning

confidence: 99%

“…This biomarker denotes the presence of ovarian and reproductive cancers in women, with serum concentrations of CA125 greater than 35 U/ml considered indicative of potential malignancies [3]. Interpretation of rising CA125 levels in diagnosed patients continues to be a topic of conversation among clinicians [4].…”

Section: Introductionmentioning

confidence: 99%

Conflicting Views on the Molecular Structure of the Cancer Antigen CA125/MUC16

Bouanene

Miled

2010

Disease Markers

View full text Add to dashboard Cite

Abstract. CA125 is a tumor antigen used to monitor the progression and regression of epithelial ovarian cancer. Despite the widespread use of CA125, the biochemical and molecular nature of this antigen is poorly understood. Analysis of the structure of CA125 is essential for determining the physiological role of this very significant tumor marker. Accumulated experimental evidence has shown that CA125 epitopes reside on a molecule of very complex architecture in terms of both protein backbone and oligosaccharide structures. It is not clear whether the heterogeneity of CA125 molecular characteristics are due to the variability of biological sources from which the molecule was isolated or to the different biophysical methods used for the characterization of all the oligosaccharides linked to CA125 or to the presence of glycoisoforms for this protein. This review attempts to summarize emerging data related to molecular characteristics of CA125 and to compare approaches undertaken to reach a better understanding of molecular features of this tumor marker.

show abstract

“…Considering the high importance and potential application in the early diagnosis of cancer, detection of tumor markers has received more and more attention [19–23]. While some novel immunoassays have been developed [24–33], a variety of techniques have been employed for the development of these assays. Table 2 summarizes some examples of immunoassays which have been developed for tumor markers analysis [33–49].…”

Section: Introductionmentioning

confidence: 99%

Colorimetric Immunoassay for Detection of Tumor Markers

Yin

Cao

et al. 2010

IJMS

View full text Add to dashboard Cite

Tumor markers are substances, usually proteins, produced by the body in response to cancer growth, or by the cancer tissue itself. They can be detected in blood, urine, or tissue samples, and the discovery and detection of tumor markers may provide earlier diagnosis of cancer and improved therapeutic intervention. Colorimetric immunoassays for tumor marker detection have attracted considerable attention, due to their simplicity and high efficiency. The traditionally used colorimetric immunoassays for the detection of tumor markers are based on enzyme-linked immunosorbent assays, and the great achievement of nanotechnology has further opened opportunities for the development of such kind of immunoassays. This paper will summarize recent advances in the field of colorimetric immunoassays for detecting tumor markers, which is aimed to provide an overview in this field, as well as experimental guidance for the learner.

show abstract

Novel fluoroimmunoassay for ovarian cancer biomarker CA-125

Cited by 33 publications

References 9 publications

Enhanced immuno-detection of shed extracellular domain of HER-2/neu

Enhanced immuno-detection of shed extracellular domain of HER-2/neu

Conflicting Views on the Molecular Structure of the Cancer Antigen CA125/MUC16

Colorimetric Immunoassay for Detection of Tumor Markers

Contact Info

Product

Resources

About